Semaglutide, a glucagon like peptide 1 (GLP 1) receptor agonist, has well established weight loss benefits. Cagrilintide, a long acting analogue of the satiety hormone amylin, has shown promise for weight loss in early trials. The potential benefit Development of Cagrilintide, a Long Acting Amylin Analogue ScienceDirect Structural and dynamic features of cagrilintide binding to calcitonin and amylin receptors Nature Communications Characterization and Impurity Profiling of Combined Amylin and GLP 1 Analogs with RapiZyme Trypsin Waters